Partnering News

09.12.2016

Circle Pharma enters into an agreement with Pfizer to build screening library of macrocyclic peptides

09.08.2016

AnTolRx, Inc. Announces Series A Equity Funding from Pfizer, JDRF and Orion Equity Partners, LLC to Develop Targeted Nanoparticle Tolerance Therapeutics

07.26.2016

BIND Therapeutics Determines Pfizer’s $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND’s Assets

07.25.2016

Spark Therapeutics and Pfizer Announce Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity

07.01.2016

BIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer Inc.

06.14.2016

Shire to License PF-00547659 from Pfizer, Adding to Established and Leading Gastrointestinal Portfolio

06.05.2016

Weizmann Institute of Science Announces Visiting Scientist Agreement with Pfizer Inc.

05.31.2016

BioRap Technologies to enter strategic collaboration with Pfizer Inc. to research and develop novel immunomodulators

05.10.2016

AM‐Pharma publishes safety and pharmacokinetic data from Phase I recAP trial

05.10.2016

First Dosing of Pfizer DART Candidate in Phase 1 Study Triggers Milestone Payment to MacroGenics

05.05.2016

WAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically Targeted Therapies for the Treatment of Metabolic Diseases

04.26.2016

AM‐Pharma receives FDA fast track designation for recAP in Acute Kidney Injury, and reports completion of first stage in Phase II trial